Jury Ruling Boosts Qualcomm, Weakens Arm in High-Stakes Licensing Battle

GuruFocus.com
24 Dec 2024

After a federal jury decided in favor of the San Diego-based chipmaker on two of three counts, analysts said Monday that Qualcomm (NASDAQ:QCOM) emerged with a "clear win" in its legal struggle with Arm Holdings (NASDAQ:ARM).Arm's stock sank 2.6%; Qualcomm's shares rose 2% in premarket trade. Stacy Rasgon, a Bernstein analyst, emphasized the importance of the jury's discovery that Arm architecture license of Qualcomm's CPUs licensed under Nuvia's designs is owned by the business. For Qualcomm and its CEO Cristiano Amon, Rasgon termed the outcome a "decisive victory".

  • Warning! GuruFocus has detected 5 Warning Signs with QCOM.

On Qualcomm, Rasgon kept an Outperform rating and a $215 price target; on Arm, he assigned an Underweight rating and a $100 target. Since there were no agreement terms broken, he pointed out that the jury's conclusions made Arm unlikely to revoke Qualcomm's architectural license.Analyst Aaron Rakers of Wells Fargo called the result a "key win" for Qualcomm, therefore setting the standard for any retrial Arm requests.

Though they were deadlocked on whether Nuvia itself breached its architectural license, the jury also decided in Qualcomm's favor over possible breaches of that license. The outcome strengthens Qualcomm's license posture going ahead and guarantees its CPU roadmap.

This article first appeared on GuruFocus.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10